Keywords: Daiichi Sankyo, Nine months 2010 financial results, Ranbaxy
Japan’s Daiichi Sankyo says nine-month 2010 sales boosted by Ranbaxy, but sees 4th-qtr loss due to interest costs at the Indian unit
Article | 01 February 2011
In the nine months to December 31, 2010, Japan’s third-largest drugmaker Daiichi Sankyo (TYO: 4568) and its consolidated subsidiaries posted net ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
